Stock Mumak

Stock Profile

Johnson & Johnson

Thanks to a strong pipeline, robust cash flows and a defensive business model, Johnson & Johnson remains a high-quality healthcare investment.

Stock Snapshot

JNJ Logo
Table HeaderTable Header
CompanyJohnson & Johnson
SectorHealthcare
ThemeQuality stock in the healthcare sector with strong dividend growth, an oncology focus, and robust financial strength.
Business ModelGlobal healthcare company with a focus on innovative medicines, oncology, immunology, and medical technology
ISINUS4781601046
Market Capitalizationapprox. $609 billion USD
UMBRELLA StatusActive

Mumak Score Card

Geopolitics

Industry

Fundamentals

Sentiment

Technical Analysis

Price Performance (12 Months)

Aktuelle Unternehmensmeldungen

Johnson & Johnson
Healthcare

Valuation Analysis: Johnson & Johnson

ISIN: US4781601046

Johnson & Johnson is one of the world’s leading healthcare companies. The company benefits from a strong position in pharmaceuticals and medical technology, a robust innovation pipeline, and an exceptionally solid balance sheet.
Compass 5 out of 5
Active icon
More research

Latest Portfolio Updates

Tesla, Inc.
Company Update

Tesla – Q2 2026 Earnings Update

Tesla delivered record revenue and strong vehicle deliveries in Q2 2026. However, heavy investment in AI and robotics weighed on
Next Update
Johnson & Johnson
Company Update

Johnson & Johnson – Q2 2026 Earnings Update

Johnson & Johnson impresses with strong Q2 2026 figures, significantly increasing revenue and free cash flow while raising its guidance
Next Update
Weekly Update

Weekly Market Overview – July 13-19, 2026

IBM's earnings warning rattles the stock markets. Why fundamental data, quarterly results, and company outlooks are once again the most
Next Update
Weekly Update

Weekly Market Overview – June 29–July 5, 2026

The healthcare sector remains in the lead, while technology and defense stocks are regaining strength. Positive impulses for the UMBRELLA
Next Update